Moclobemide as an MAO-A assay reference
Biochemical assay · Recombinant MAO-A in a cell-free fluorometric assay using tyramine and Ampliflu Red/horseradish peroxidase. Species is not specified in Section 2.2. [1]
Moclobemide inhibited MAO-A with a reported IC50 of 6.061 ± 0.262 µM (mean ± SD). Blank, DMSO control, peroxidase-interference and non-enzymatic fluorescence checks are described. The paper’s competitive/reversible kinetic conclusion concerns compound 3e and is not assigned to moclobemide.
| Endpoint | Reported result | Reference |
|---|---|---|
| Half-maximal inhibition of recombinant MAO-A | IC50 6.061 ± 0.262 µM (mean ± SD) | [1] |
Literature-Reported Treatment Conditions
- Treatment concentration
- 10⁻³–10⁻⁹ M inhibitor solutions, as reported; this range is distinct from the fitted IC50.
- Exposure duration
- 30 min inhibitor–enzyme preincubation at 37 °C; 30 min reaction at 37 °C with fluorescence measured at 5 min intervals.
- Method
- Cell-free enzyme inhibition assay with tyramine as substrate.
- Vehicle
- Inhibitor solutions prepared in 2% DMSO; vehicle controls replace inhibitor solution with the same 20 µL of 2% DMSO. This is not a claim of 2% final-well DMSO.
- Reported limits
- Moclobemide salt, lot/purity, enzyme species and independent assay-repeat count are not specified in the selected methods. No moclobemide MAO-B result is supplied in Table 2 (dash entries).
Methods and source locations
Compound reported in the paper: Moclobemide; Compound label in the paper: moclobemide
Evidence concerns the named compound and reported source material; it does not validate Adooq material, purity or a lot.
Section 2.2; Section 3.2; Tables 2–3, moclobemide rows
Half-maximal inhibition of recombinant MAO-A: Fluorescence Ex/Em 535/587 nm; inhibitor/blank/control concentrations analyzed in quadruplicate; dose-response fitting in GraphPad Prism 5.0. Independent repeat-assay count not specified. — Table 3, moclobemide IC50 column; Section 2.2